S
S.R. David
Researcher at Eli Lilly and Company
Publications - 20
Citations - 2635
S.R. David is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Olanzapine & Placebo. The author has an hindex of 10, co-authored 20 publications receiving 2570 citations.
Papers
More filters
Journal ArticleDOI
Olanzapine Versus Placebo in the Treatment of Acute Mania
Mauricio Tohen,Todd M. Sanger,Susan L. McElroy,G.D. Tollefson,K. N. R. Chengappa,D. G. Daniel,Frederick Petty,Franca Centorrino,R. Wang,S. L. Grundy,M. Greaney,T. Jacobs,S.R. David,V. Toma +13 more
TL;DR: The olanzapine group experienced significantly greater mean mean scores than the placebo group in the treatment of acute mania, and the primary efficacy measure was defined as a change from baseline to endpoint in total score on the Young Mania Rating Scale.
Journal ArticleDOI
Neuropsychological Change in Early Phase Schizophrenia During 12 Months of Treatment With Olanzapine, Risperidone, or Haloperidol
Scot E. Purdon,Barry Jones,Barry Jones,E. Stip,Alan Labelle,Don Addington,S.R. David,Alan Breier,Gary D. Tollefson +8 more
TL;DR: Olanzapine has some superior cognitive benefits relative to haloperidol and risperidone, and a larger sample replication study is necessary to confirm and generalize the observations of this study.
Journal ArticleDOI
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
Padraig Wright,Martin Birkett,S.R. David,Karena Meehan,Iris Ferchland,Karla Alaka,John C. Saunders,John A. Krueger,Patrice Bradley,Luis San,Miguel Bernardo,Michael Reinstein,Alan Breier +12 more
TL;DR: Intramuscular olanzapine represents a rapid, effective, and safe treatment for acute agitation in schizophrenia.
Journal ArticleDOI
Olanzapine versus placebo in the treatment of acute mania
Mauricio Tohen,Todd M. Sanger,Susan L. McElroy,G.D. Tollefson,S. L. Grundy,M. Greaney,T. Jacobs,S.R. David,Scott W. Andersen,V. Toma +9 more
TL;DR: The results from this study suggest that compared with placebo, olanzapine has superior efficacy for the symptoms of acute mania.
Journal ArticleDOI
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
Alan Breier,Karena Meehan,Karena Meehan,Martin Birkett,S.R. David,Iris Ferchland,Virginia K. Sutton,Cindy C. Taylor,Rebecca Palmer,Martin Dossenbach,Geri Kiesler,Shlomo Brook,Padraig Wright,Padraig Wright +13 more
TL;DR: Intramuscular olanzapine at a dose of 2.5 to 10.0 mg per injection exhibits a dose-response relationship in the rapid treatment of acute agitation in patients with schizophrenia and demonstrates a favorable safety profile.